HPLC purity
Reverse-phase HPLC with UV detection; ≥99% area purity target with related-substance reporting on request.
PeptiOEM · Catalog · Semaglutide
GLP-1 family · Engine 2 (OUS only)
Semaglutide OEM supply.
OUS markets & research only.
Lyophilized semaglutide for OUS (non-US) distribution, research labs, and private-label brand evaluation outside the United States. 99%+ HPLC purity, per-batch COA + MS.
!
OUS & research only — not for US compounding under FDA 2026 proposal
On 2026-04-30 the FDA proposed removing GLP-1 medications from the 503B bulks list, with public comment open through 2026-06-29. Pending finalization, semaglutide cannot be compounded from bulk substances by US 503B facilities. Read the GLP-1 2026 update →
Lot SEM-5HPLC ≥ 99%MS confirmed2 / 5 / 10 / 20 mg
Vial illustrations reflect supplied lyophilized format. Distribution scope and destination market confirmed before invoicing.
| Compound | Semaglutide |
|---|---|
| Class | GLP-1 receptor agonist (research) |
| Molecular weight | ≈ 4113.6 g/mol |
| Form | Lyophilized powder, sterile glass vial |
| Purity target | ≥ 99% by HPLC |
| Vial formats | 2, 5, 10, 20 mg |
| Documentation | COA + HPLC + MS, per-batch lot file |
| Distribution scope | OUS markets & research only |
| Storage | 2–8 °C protected from light; long-term −20 °C |
MOQ & lead time
| Tier | Quantity | Lead time |
|---|---|---|
| Sample lot | From 100 vials | 5–10 days |
| Production lot | 500–2,000 vials | 14–21 days |
| OEM repeat (OUS) | 2,000+ vials | 21–28 days, scheduled |
Semaglutide is off-patent in India and China as of 2026 — OUS distribution and generic supply pathways are opening. All quotes require a destination country and buyer track.
Documentation
Per-batch document pack on every semaglutide lot.
COA, HPLC chromatogram, MS identity, water content, and lot file. Distribution scope confirmed before invoicing.
MS identity
Mass spectrometry identity confirmation against the semaglutide reference profile.
Destination check
Buyer track and destination country reviewed against the FDA 2026 503B bulks proposal before quoting.
FAQ
Semaglutide — frequently asked by B2B buyers.
Why is semaglutide marked OUS-only?
The FDA's 2026-04-30 proposal would remove GLP-1 medications, including semaglutide, from the 503B bulks list, with public comment open through 2026-06-29. Pending finalization, US 503B facilities cannot compound semaglutide from bulk substances. PeptiOEM positions semaglutide for OUS distribution, research, and private-label brand evaluation rather than US compounding.
Is semaglutide off-patent in some countries?
Yes. Novo Nordisk's semaglutide patent expires in 2026 in several countries including India and China, opening OUS distribution and generic supply pathways. We supply lyophilized semaglutide into compliant OUS markets.
Which markets do you serve for semaglutide?
India, Brazil, Mexico, Indonesia and select EMEA distributors with appropriate local registration; case-by-case review for other markets. Destination country is confirmed before quoting.
Can research labs source semaglutide?
Yes — lyophilized semaglutide is supplied for laboratory research with COA, HPLC, and MS documentation.
What does your COA report?
HPLC purity (target ≥99%), MS identity, water content, related-substance profile on request, and lot traceability tied to the document pack.
Related compounds